Cytodyn Inc (CYDY) 1.0500 $CYDY
Patients Approach Two Years of Complete HIV Viral Load Suppression in Phase 2b PRO 140 Monotherapy Extension Study
GlobeNewswire - Tue Aug 23, 5:30AM CDT
CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new antibody therapies for combating human immunodeficiency virus (HIV) infection, announces that the first of 11 HIV-1 patients receiving PRO 140 as a monotherapy in a Phase 2b extension study has reached two years of complete virologic suppression. Four additional patients are expected to reach the two-year benchmark in the next three weeks and five more patients are expected to reach this benchmark in approximately two months.
UPDATE: ASM Microbe 2016 Presentation of Clinical Results From CytoDyn's Phase 2b Monotherapy Extension Study Now Available
GlobeNewswire - Thu Jun 23, 6:00PM CDT
CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new monoclonal antibody therapies for combating human immunodeficiency virus (HIV) infection, announces the availability of Paul J. Maddon, M.D., Ph.D.'s June 20 presentation at the ASM Microbe 2016 Conference discussing clinical results from the Company's Phase 2b monotherapy extension study in patients with HIV on CytoDyn's website. Dr. Maddon's presentation can also be accessed by inserting the following link into your browser:
StockNewsNow.com Publishes New SNNLive Video Interview with CytoDyn Inc. Discussing Clinical Development
PR Newswire - Wed Jun 22, 12:39PM CDT
StockNewsNow.com, The Official MicroCap News Source(TM), today published an SNNLive Video Interview with Dr. Nader Pourhassan, President & CEO of CytoDyn Inc. (OTCQB: CYDY), a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of HIV infection, according to the company's website (see here: www.CytoDyn.com). The video interview was recorded on Tuesday, June 7th, 2016, at the LD Micro Invitational in Bel Air, CA.
ASM Microbe 2016 Presentation of Clinical Results From CytoDyn's Phase 2b Monotherapy Extension Study Now Available
GlobeNewswire - Wed Jun 22, 5:30AM CDT
CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new monoclonal antibody therapies for combating human immunodeficiency virus (HIV) infection, announces the availability of Paul J. Maddon, M.D., Ph.D.'s June 20 presentation at the ASM Microbe 2016 Conference discussing clinical results from the Company's Phase 2b monotherapy extension study in patients with HIV on CytoDyn's website. Dr. Maddon's presentation can also be accessed by inserting the following link into your browser:
CytoDyn's PRO 140 Phase 2b HIV Monotherapy Trial Findings to be Presented at ASM Microbe 2016 Conference on June 20
GlobeNewswire - Fri Jun 17, 5:30AM CDT
CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new monoclonal antibody therapies for combating human immunodeficiency virus (HIV) infection, announces that clinical data from the Company's PRO 140 monotherapy phase 2b extension study in patients with HIV will be presented at the American Society for Microbiology's ASM Microbe 2016 Conference on Monday, June 20, 2016. As previously announced, an abstract of the clinical data is available online on the ASM Microbe 2016 website at: http://www.abstractsonline.com/pp8/#!/4060/pr...tion/16215.
CytoDyn to Present at LD Micro Invitational Conference on June 7
GlobeNewswire - Thu Jun 02, 5:30AM CDT
CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new monoclonal antibody therapies for combating human immunodeficiency virus (HIV) infection, announces that Nader Z. Pourhassan, Ph.D., President and CEO, will present at the LD Micro Invitational Conference on June 7, at 8:30 a.m. Pacific Time (11:30 a.m. Eastern Time). The conference is being held at the Luxe Sunset Hotel in Los Angeles.
Clinical Abstract from CytoDyn's PRO 140 Phase 2b HIV Monotherapy Trial Now Available on ASM Microbe 2016 Conference Website
GlobeNewswire - Mon May 16, 3:32PM CDT
CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new monoclonal antibody therapies for combating human immunodeficiency virus (HIV) infection, announces that an abstract featuring clinical data from the Company's PRO 140 monotherapy Phase 2b extension study in patients with HIV is now available online on the ASM Microbe 2016 website at: http://www.abstractsonline.com/pp8/#!/4060/pr...tion/16215.
CytoDyn Announces Investment Community Conference Call for May 11, 2016
GlobeNewswire - Mon May 09, 1:28PM CDT
CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new antibody therapies for combating human immunodeficiency virus (HIV) infection, announces that management will hold an investment community conference call on Wednesday, May 11, 2016, at 1:00 p.m. PT / 4:00 p.m. ET to provide an update on clinical and regulatory developments.
CytoDyn's Compassionate Use Protocol Receives FDA Clearance to Proceed
GlobeNewswire - Tue May 03, 5:00AM CDT
CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new antibody therapies for combating human immunodeficiency virus (HIV) infection, announces that it has received clearance from the FDA to proceed with its compassionate use protocol, which was submitted to the Agency on April 14. The compassionate use protocol will enable the first patient enrolled in the PRO 140_CD02 Phase 3 pivotal trial with PRO 140 in combination with HAART therapy to remain on PRO 140 upon successful conclusion of the Phase 3 trial period.
CytoDyn Reports Complete Viral Load Suppression in HIV-Infected Patients for Up to 20 Months in PRO 140 Monotherapy Extension Study
GlobeNewswire - Mon Apr 18, 5:00AM CDT
CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new antibody therapies for combating human immunodeficiency virus (HIV) infection, announces that 10 HIV-infected patients in its ongoing PRO 140 monotherapy extension study have achieved complete viral load suppression for at least 18 months, with several patients approaching 20 months. This ongoing monotherapy study is an extension of the completed CDI-01 Phase 2b study that evaluated PRO 140 as a monotherapy in treatment-experienced patients with the R5 subtype of HIV. One patient recently dropped out of the extension study following 17 months of full HIV viral load suppression.
CytoDyn Files a Compassionate Use Protocol With FDA
GlobeNewswire - Thu Apr 14, 8:00AM CDT
CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new antibody therapies for combating human immunodeficiency virus (HIV) infection, announced today that it filed with the FDA a protocol for a compassionate use of PRO 140 to allow a patient who is reaching the end of the Phase 3 combination study to continue treatment with PRO 140 for an extended period of time. This compassionate use protocol will enable the patient to remain on PRO 140 upon successful conclusion of their 25-week participation in the trial.
Small Company That Could Change the Way HIV is Treated
ACCESSWIRE - Mon Apr 04, 8:03AM CDT
VANCOUVER, WA / ACCESSWIRE / April 4, 2016 / CytoDyn (OTCQB: CYDY) is a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses. CytoDyn's lead product candidate, PRO 140, has the potential to drive groundbreaking advancements in developing the next generation of HIV treatments.
CytoDyn to Present PRO 140 Monotherapy Clinical Results at ASM Microbe 2016 Conference
GlobeNewswire - Mon Mar 28, 5:30AM CDT
CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV) infection, today announced that clinical findings from the Company's PRO 140 monotherapy phase 2b study will be presented in an oral slide session at the ASM Microbe 2016 Conference from June 16 - 20 in Boston, MA.
CytoDyn Announces Investment Community Conference Call for March 24, 2016
GlobeNewswire - Tue Mar 22, 3:01PM CDT
CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV) infection, today announced that management will hold an investment community conference call on Thursday, March 24, 2016, at 1:00 p.m. PT / 4:00 p.m. ET to provide an update on clinical and regulatory developments.
HIV / AIDS Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 09, 10:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/zx8ggt/hiv_aids) has announced the addition of the "HIV / AIDS - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for HIV / AIDSand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - HIV / AIDSOverview - Therapeutics Development - Pipeline Products for HIV / AIDS - Overview - Pipeline Products for HIV / AIDS - Comparative Analysis - HIV / AIDS - Therapeutics under Development by Companies - HIV / AIDS - Therapeutics under Investigation by Universities/Institutes - HIV / AIDS - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - HIV / AIDS - Products under Development by Companies - HIV / AIDS - Products under Investigation by Universities/Institutes - HIV / AIDS - Companies Involved in Therapeutics Development Companies Mentioned - Sample List - Abivax S.A. - Adaptimmune Limited - AiCuris GmbH & Co. KG - Akshaya Bio Inc. - Altor BioScience Corporation - AltraVax Inc. - Amarna Therapeutics B.V. - American Gene Technologies International Inc. - Amplyx Pharmaceuticals, Inc. - Antigen Express, Inc. - Aphios Corporation - Apotex, Inc. - Argos Therapeutics, Inc. - Arno Therapeutics, Inc. - Avexa Limited - BCI Pharma - Beth Israel Deaconess Medical Center, Inc. - BioClonetics Immunotherapeutics, Inc. - Bionor Pharma ASA - Biosantech SA - BioSource Pharm, Inc. - Biotron Limited - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - C4X Discovery Limited - Calimmune, Inc. - Celldex Therapeutics, Inc. - Chipscreen Biosciences Ltd - Cocrystal Pharma, Inc. - CompleGen, Inc. - Critical Outcome Technologies Inc. - CureVac GmbH - Cytodyn Inc. For more information visit http://www.researchandmarkets.com/research/zx8ggt/hiv_aids
ARGS: 5.07 (+0.21), CLDX: 3.44 (-0.05), BMY: 58.66 (-0.11)
Studying the Charts -- New Research on Cardinal Resources, Cannabis Science, OriginClear and CytoDyn
ACCESSWIRE - Tue Feb 02, 6:35AM CST
NEW YORK, NY / ACCESSWIRE / February 2, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Cardinal Resources Inc. (OTC: CDNL), Cannabis Science Inc. (OTC: CBIS), OriginClear Inc. (OTC: OOIL) and CytoDyn Inc. (OTC: CYDY). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
A Look Inside the Chart, Technical Insights - Analyst Notes on Hybrid Coating Technologies, Force Protection Video Equipment, CytoDyn and Golden Queen Mining
ACCESSWIRE - Mon Feb 01, 7:35AM CST
NEW YORK, NY / ACCESSWIRE / February 1, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Hybrid Coating Technologies Inc. (OTC: HCTI), Force Protection Video Equipment Corp. (OTC: FPVD), CytoDyn Inc. (OTC: CYDY) and Golden Queen Mining Co. Ltd. (OTC: GQMNF). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
CytoDyn Inc. (OTCQB: CYDY) Analyst Coverage Initiated
ACCESSWIRE - Mon Feb 01, 7:01AM CST
NEW YORK, NY / ACCESSWIRE / February 1, 2016 / CytoDyn Inc. (OTCQB: CYDY) a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV) infection, today announced the Company filed a request for Breakthrough Therapy Designation with the FDA for PRO 140 as a Treatment for HIV-1 Infection in Treatment-Experienced Patients with Virologic Failure. While the standard of care for HIV infection has been the combination of medications from different antiretroviral (ART) classes that interfere with different steps of the viral lifecycle, there is now a significant number of long-term survivors who are facing issues of drug resistance and are in need of new treatment options (Pennings 2013, Cossarini et al. 2013). The Company believes this request for Breakthrough Therapy Designation addresses the unmet need for novel therapies for the growing number of heavily treatment-experienced HIV patients, who face a dwindling pool of effective therapeutic options in the face of uncontrolled viral load and low CD4+ T-cell counts.
CytoDyn Reports Full Virologic Suppression in Eleven HIV Patients on PRO 140 Monotherapy for Up to 17 Months
GlobeNewswire - Thu Jan 28, 5:30AM CST
CytoDyn Inc. (OTC.QB: CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV) infection, today announced that 11 patients have achieved full virologic suppression in the Phase 2b extension study evaluating long-term suppression of HIV replication by PRO 140 monotherapy. These patients self-administered PRO 140 weekly for 14 to 17 months. Using a very sensitive, single-copy HIV-1 RNA assay, seven of 10 patients had less than one viral copy per milliliter in their blood in the most recent month of treatment. The median of the lowest HIV RNA levels detected in these 10 patients was 0.4 viral copies per milliliter of blood.
CytoDyn Files Request for Breakthrough Therapy Designation With the FDA for Use of PRO 140 in HIV Therapy
GlobeNewswire - Fri Jan 22, 5:30AM CST
CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV) infection, today announced the Company filed a request for Breakthrough Therapy Designation with the FDA for PRO 140 as a Treatment for HIV-1 Infection in Treatment-Experienced Patients with Virologic Failure.
Patients Approach Two Years of Complete HIV Viral Load Suppression in Phase 2b PRO 140 Monotherapy Extension Study
GlobeNewswire - Tue Aug 23, 5:30AM CDT
CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new antibody therapies for combating human immunodeficiency virus (HIV) infection, announces that the first of 11 HIV-1 patients receiving PRO 140 as a monotherapy in a Phase 2b extension study has reached two years of complete virologic suppression. Four additional patients are expected to reach the two-year benchmark in the next three weeks and five more patients are expected to reach this benchmark in approximately two months.
UPDATE: ASM Microbe 2016 Presentation of Clinical Results From CytoDyn's Phase 2b Monotherapy Extension Study Now Available
GlobeNewswire - Thu Jun 23, 6:00PM CDT
CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new monoclonal antibody therapies for combating human immunodeficiency virus (HIV) infection, announces the availability of Paul J. Maddon, M.D., Ph.D.'s June 20 presentation at the ASM Microbe 2016 Conference discussing clinical results from the Company's Phase 2b monotherapy extension study in patients with HIV on CytoDyn's website. Dr. Maddon's presentation can also be accessed by inserting the following link into your browser:
StockNewsNow.com Publishes New SNNLive Video Interview with CytoDyn Inc. Discussing Clinical Development
PR Newswire - Wed Jun 22, 12:39PM CDT
StockNewsNow.com, The Official MicroCap News Source(TM), today published an SNNLive Video Interview with Dr. Nader Pourhassan, President & CEO of CytoDyn Inc. (OTCQB: CYDY), a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of HIV infection, according to the company's website (see here: www.CytoDyn.com). The video interview was recorded on Tuesday, June 7th, 2016, at the LD Micro Invitational in Bel Air, CA.
ASM Microbe 2016 Presentation of Clinical Results From CytoDyn's Phase 2b Monotherapy Extension Study Now Available
GlobeNewswire - Wed Jun 22, 5:30AM CDT
CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new monoclonal antibody therapies for combating human immunodeficiency virus (HIV) infection, announces the availability of Paul J. Maddon, M.D., Ph.D.'s June 20 presentation at the ASM Microbe 2016 Conference discussing clinical results from the Company's Phase 2b monotherapy extension study in patients with HIV on CytoDyn's website. Dr. Maddon's presentation can also be accessed by inserting the following link into your browser:
CytoDyn's PRO 140 Phase 2b HIV Monotherapy Trial Findings to be Presented at ASM Microbe 2016 Conference on June 20
GlobeNewswire - Fri Jun 17, 5:30AM CDT
CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new monoclonal antibody therapies for combating human immunodeficiency virus (HIV) infection, announces that clinical data from the Company's PRO 140 monotherapy phase 2b extension study in patients with HIV will be presented at the American Society for Microbiology's ASM Microbe 2016 Conference on Monday, June 20, 2016. As previously announced, an abstract of the clinical data is available online on the ASM Microbe 2016 website at: http://www.abstractsonline.com/pp8/#!/4060/pr...tion/16215.
CytoDyn to Present at LD Micro Invitational Conference on June 7
GlobeNewswire - Thu Jun 02, 5:30AM CDT
CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new monoclonal antibody therapies for combating human immunodeficiency virus (HIV) infection, announces that Nader Z. Pourhassan, Ph.D., President and CEO, will present at the LD Micro Invitational Conference on June 7, at 8:30 a.m. Pacific Time (11:30 a.m. Eastern Time). The conference is being held at the Luxe Sunset Hotel in Los Angeles.
Clinical Abstract from CytoDyn's PRO 140 Phase 2b HIV Monotherapy Trial Now Available on ASM Microbe 2016 Conference Website
GlobeNewswire - Mon May 16, 3:32PM CDT
CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new monoclonal antibody therapies for combating human immunodeficiency virus (HIV) infection, announces that an abstract featuring clinical data from the Company's PRO 140 monotherapy Phase 2b extension study in patients with HIV is now available online on the ASM Microbe 2016 website at: http://www.abstractsonline.com/pp8/#!/4060/pr...tion/16215.
CytoDyn Announces Investment Community Conference Call for May 11, 2016
GlobeNewswire - Mon May 09, 1:28PM CDT
CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new antibody therapies for combating human immunodeficiency virus (HIV) infection, announces that management will hold an investment community conference call on Wednesday, May 11, 2016, at 1:00 p.m. PT / 4:00 p.m. ET to provide an update on clinical and regulatory developments.
CytoDyn's Compassionate Use Protocol Receives FDA Clearance to Proceed
GlobeNewswire - Tue May 03, 5:00AM CDT
CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new antibody therapies for combating human immunodeficiency virus (HIV) infection, announces that it has received clearance from the FDA to proceed with its compassionate use protocol, which was submitted to the Agency on April 14. The compassionate use protocol will enable the first patient enrolled in the PRO 140_CD02 Phase 3 pivotal trial with PRO 140 in combination with HAART therapy to remain on PRO 140 upon successful conclusion of the Phase 3 trial period.
CytoDyn Reports Complete Viral Load Suppression in HIV-Infected Patients for Up to 20 Months in PRO 140 Monotherapy Extension Study
GlobeNewswire - Mon Apr 18, 5:00AM CDT
CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new antibody therapies for combating human immunodeficiency virus (HIV) infection, announces that 10 HIV-infected patients in its ongoing PRO 140 monotherapy extension study have achieved complete viral load suppression for at least 18 months, with several patients approaching 20 months. This ongoing monotherapy study is an extension of the completed CDI-01 Phase 2b study that evaluated PRO 140 as a monotherapy in treatment-experienced patients with the R5 subtype of HIV. One patient recently dropped out of the extension study following 17 months of full HIV viral load suppression.
CytoDyn Files a Compassionate Use Protocol With FDA
GlobeNewswire - Thu Apr 14, 8:00AM CDT
CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new antibody therapies for combating human immunodeficiency virus (HIV) infection, announced today that it filed with the FDA a protocol for a compassionate use of PRO 140 to allow a patient who is reaching the end of the Phase 3 combination study to continue treatment with PRO 140 for an extended period of time. This compassionate use protocol will enable the patient to remain on PRO 140 upon successful conclusion of their 25-week participation in the trial.
Small Company That Could Change the Way HIV is Treated
ACCESSWIRE - Mon Apr 04, 8:03AM CDT
VANCOUVER, WA / ACCESSWIRE / April 4, 2016 / CytoDyn (OTCQB: CYDY) is a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses. CytoDyn's lead product candidate, PRO 140, has the potential to drive groundbreaking advancements in developing the next generation of HIV treatments.
CytoDyn to Present PRO 140 Monotherapy Clinical Results at ASM Microbe 2016 Conference
GlobeNewswire - Mon Mar 28, 5:30AM CDT
CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV) infection, today announced that clinical findings from the Company's PRO 140 monotherapy phase 2b study will be presented in an oral slide session at the ASM Microbe 2016 Conference from June 16 - 20 in Boston, MA.
CytoDyn Announces Investment Community Conference Call for March 24, 2016
GlobeNewswire - Tue Mar 22, 3:01PM CDT
CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV) infection, today announced that management will hold an investment community conference call on Thursday, March 24, 2016, at 1:00 p.m. PT / 4:00 p.m. ET to provide an update on clinical and regulatory developments.
HIV / AIDS Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 09, 10:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/zx8ggt/hiv_aids) has announced the addition of the "HIV / AIDS - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for HIV / AIDSand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - HIV / AIDSOverview - Therapeutics Development - Pipeline Products for HIV / AIDS - Overview - Pipeline Products for HIV / AIDS - Comparative Analysis - HIV / AIDS - Therapeutics under Development by Companies - HIV / AIDS - Therapeutics under Investigation by Universities/Institutes - HIV / AIDS - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - HIV / AIDS - Products under Development by Companies - HIV / AIDS - Products under Investigation by Universities/Institutes - HIV / AIDS - Companies Involved in Therapeutics Development Companies Mentioned - Sample List - Abivax S.A. - Adaptimmune Limited - AiCuris GmbH & Co. KG - Akshaya Bio Inc. - Altor BioScience Corporation - AltraVax Inc. - Amarna Therapeutics B.V. - American Gene Technologies International Inc. - Amplyx Pharmaceuticals, Inc. - Antigen Express, Inc. - Aphios Corporation - Apotex, Inc. - Argos Therapeutics, Inc. - Arno Therapeutics, Inc. - Avexa Limited - BCI Pharma - Beth Israel Deaconess Medical Center, Inc. - BioClonetics Immunotherapeutics, Inc. - Bionor Pharma ASA - Biosantech SA - BioSource Pharm, Inc. - Biotron Limited - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - C4X Discovery Limited - Calimmune, Inc. - Celldex Therapeutics, Inc. - Chipscreen Biosciences Ltd - Cocrystal Pharma, Inc. - CompleGen, Inc. - Critical Outcome Technologies Inc. - CureVac GmbH - Cytodyn Inc. For more information visit http://www.researchandmarkets.com/research/zx8ggt/hiv_aids
ARGS: 5.07 (+0.21), CLDX: 3.44 (-0.05), BMY: 58.66 (-0.11)
Studying the Charts -- New Research on Cardinal Resources, Cannabis Science, OriginClear and CytoDyn
ACCESSWIRE - Tue Feb 02, 6:35AM CST
NEW YORK, NY / ACCESSWIRE / February 2, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Cardinal Resources Inc. (OTC: CDNL), Cannabis Science Inc. (OTC: CBIS), OriginClear Inc. (OTC: OOIL) and CytoDyn Inc. (OTC: CYDY). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
A Look Inside the Chart, Technical Insights - Analyst Notes on Hybrid Coating Technologies, Force Protection Video Equipment, CytoDyn and Golden Queen Mining
ACCESSWIRE - Mon Feb 01, 7:35AM CST
NEW YORK, NY / ACCESSWIRE / February 1, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Hybrid Coating Technologies Inc. (OTC: HCTI), Force Protection Video Equipment Corp. (OTC: FPVD), CytoDyn Inc. (OTC: CYDY) and Golden Queen Mining Co. Ltd. (OTC: GQMNF). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
CytoDyn Inc. (OTCQB: CYDY) Analyst Coverage Initiated
ACCESSWIRE - Mon Feb 01, 7:01AM CST
NEW YORK, NY / ACCESSWIRE / February 1, 2016 / CytoDyn Inc. (OTCQB: CYDY) a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV) infection, today announced the Company filed a request for Breakthrough Therapy Designation with the FDA for PRO 140 as a Treatment for HIV-1 Infection in Treatment-Experienced Patients with Virologic Failure. While the standard of care for HIV infection has been the combination of medications from different antiretroviral (ART) classes that interfere with different steps of the viral lifecycle, there is now a significant number of long-term survivors who are facing issues of drug resistance and are in need of new treatment options (Pennings 2013, Cossarini et al. 2013). The Company believes this request for Breakthrough Therapy Designation addresses the unmet need for novel therapies for the growing number of heavily treatment-experienced HIV patients, who face a dwindling pool of effective therapeutic options in the face of uncontrolled viral load and low CD4+ T-cell counts.
CytoDyn Reports Full Virologic Suppression in Eleven HIV Patients on PRO 140 Monotherapy for Up to 17 Months
GlobeNewswire - Thu Jan 28, 5:30AM CST
CytoDyn Inc. (OTC.QB: CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV) infection, today announced that 11 patients have achieved full virologic suppression in the Phase 2b extension study evaluating long-term suppression of HIV replication by PRO 140 monotherapy. These patients self-administered PRO 140 weekly for 14 to 17 months. Using a very sensitive, single-copy HIV-1 RNA assay, seven of 10 patients had less than one viral copy per milliliter in their blood in the most recent month of treatment. The median of the lowest HIV RNA levels detected in these 10 patients was 0.4 viral copies per milliliter of blood.
CytoDyn Files Request for Breakthrough Therapy Designation With the FDA for Use of PRO 140 in HIV Therapy
GlobeNewswire - Fri Jan 22, 5:30AM CST
CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV) infection, today announced the Company filed a request for Breakthrough Therapy Designation with the FDA for PRO 140 as a Treatment for HIV-1 Infection in Treatment-Experienced Patients with Virologic Failure.
